Literature DB >> 10856696

Post-transplantation lymphoproliferative disorders: advances in diagnosis, prevention and management in children.

.   

Abstract

With improving operative and postoperative survival after pediatric thoracic transplantation, attention has appropriately begun to focus on complications of long-term immunosuppression. One important complication is post-transplantation lymphoproliferative disorders. Much has been learnt about this spectrum of disorders over the last 15 years, including the pivotal role of primary Epstein-Barr virus infection in the etiology of most cases. Despite these advances, nomenclature remains confusing for the clinician, prediction of outcome is imprecise and treatment strategies are poorly defined. Indeed, no treatments have been subjected to comparative prospective clinical trials. Only recently has attention focussed on strategies for prevention. This article will review the current state of knowledge of post-transplantation lymphoproliferative disorders, with emphasis on recent advances in diagnosis, prevention and management.

Entities:  

Year:  2000        PMID: 10856696     DOI: 10.1016/s1058-9813(00)00044-8

Source DB:  PubMed          Journal:  Prog Pediatr Cardiol        ISSN: 1058-9813


  3 in total

1.  Pediatric heart and lung transplantation.

Authors:  Subash C Reddy; Steven A Webber
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

2.  Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients.

Authors:  Elizabeth Schauer; Steven Webber; Michael Green; David Rowe
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization.

Authors:  Camille Rose; Michael Green; Steven Webber; Lawrence Kingsley; Roger Day; Simon Watkins; Jorges Reyes; David Rowe
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.